IA
CVKD icon

IFP Advisors’s Cadrenal Therapeutics CVKD Stock Holding History

IFP Advisors’s Portfolio CVKD Stock Details CVKD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$100 Hold
30
– – ﹤0.01% 4957
2026
Q1 		$154 Hold
30
– – ﹤0.01% 4663
2025
Q4 		$203 Hold
30
– – ﹤0.01% 4477
2025
Q3 		$415 Hold
30
– – ﹤0.01% 4235
2025
Q2 		$362 Hold
30
– – ﹤0.01% 4512
2025
Q1 		$529 Buy
+30
New +$552 ﹤0.01% 3453

Other funds holding CVKD

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
CA
CoreCap Advisors Southfield, Michigan $3.39B AUM 31.21% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
GBT
Grove Bank & Trust Miami, Florida $1.01B AUM 26.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
CA
Clearstead Advisors Cleveland, Ohio $10.6B AUM 24.87% 1-Year Est. Return

IFP Advisors's CVKD Position: Q2 2026 in Review

IFP Advisors held its Cadrenal Therapeutics (CVKD) position steady in Q2 2026 at 30 shares worth $100. The position accounts for ﹤0.01% of the portfolio, ranked #4957.

IFP Advisors first reported a position in CVKD in Q1 2025 and has held it in 6 quarters since. The position peaked at $529 in Q1 2025. 20 funds tracked by Wall St. Rank hold CVKD as of Q2 2026.

  • IFP Advisors held 30 shares of Cadrenal Therapeutics worth $100 as of Q2 2026.
  • IFP Advisors left its Cadrenal Therapeutics share count unchanged in Q2 2026.
  • Cadrenal Therapeutics made up ﹤0.01% of IFP Advisors's portfolio in Q2 2026, its #4957 holding.
  • IFP Advisors first reported a position in Cadrenal Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • IFP Advisors's Cadrenal Therapeutics position peaked at $529 in Q1 2025.
  • 20 funds tracked by Wall St. Rank held Cadrenal Therapeutics as of Q2 2026.

Based on IFP Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.